XML 23 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 872.5 $ 769.0
Short-term investments (Note 4) 381.7 446.3
Accounts receivable, net of allowances of $7.6 and $7.9, respectively 717.7 643.0
Other receivables 61.6 56.1
Inventories (Note 2) 914.3 875.5
Prepaid expenses 119.1 110.0
Other current assets 190.3 195.9
Total current assets 3,257.2 3,095.8
Long-term investments (Note 4) 1,066.7 1,239.0
Property, plant, and equipment, net 1,646.0 1,632.8
Operating lease right-of-use assets 88.5 92.3
Goodwill 1,308.4 1,164.3
Other intangible assets, net (Note 6) 446.8 285.2
Deferred income taxes 544.0 484.0
Other assets (Note 5) 293.6 299.1
Total assets 8,651.2 8,292.5
Current liabilities    
Accounts payable 180.8 201.9
Accrued and other liabilities (Note 2) 876.1 795.0
Operating lease liabilities 25.1 25.5
Total current liabilities 1,082.0 1,022.4
Long-term debt 596.5 596.3
Contingent consideration liabilities (Note 7) 26.9 26.2
Taxes payable 143.4 143.4
Operating lease liabilities 66.2 69.5
Uncertain tax positions 284.0 267.5
Litigation agreement accrual (Note 2) 130.1 143.0
Other liabilities 260.1 217.5
Total liabilities 2,589.2 2,485.8
Commitments and contingencies (Note 11)
Stockholders' equity    
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding           0.0 0.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 647.1 and 646.3 shares issued, and 606.0 and 608.3 shares outstanding, respectively 647.1 646.3
Additional paid-in capital 2,049.3 1,969.3
Retained earnings 7,930.5 7,590.0
Accumulated other comprehensive loss (Note 12) (255.4) (254.9)
Treasury stock, at cost, 41.1 and 38.0 shares, respectively (4,393.5) (4,144.0)
Total Edwards Lifesciences, Inc. stockholders' equity 5,978.0 5,806.7
Noncontrolling interest 84.0 0.0
Total stockholders' equity 6,062.0 5,806.7
Total liabilities and equity $ 8,651.2 $ 8,292.5